Core Insights - Adia Nutrition, Inc. is entering the $1.9 billion glutathione market with innovative IV and transdermal therapies, expanding its offerings in regenerative medicine [1][6] - The global glutathione market is projected to reach $3.9 billion by 2035, driven by increasing consumer awareness of antioxidants [6] Company Developments - Adia Med has integrated glutathione IV therapies into its treatment protocols, which include advanced stem cell and exosome therapies [3][4] - The newly introduced Glutaryl Transdermal Glutathione Spray utilizes sub-nanotechnology for enhanced skin absorption, providing a non-invasive alternative to IV therapies [5] - The addition of glutathione therapies reflects Adia Med's commitment to innovative, science-backed patient care solutions [4][7] Market Position - Adia's entry into the glutathione market strengthens its position as a leader in regenerative medicine, creating significant revenue potential for investors [6][7] - The glutathione therapies are expected to appeal to a broad audience, including athletes and wellness enthusiasts, enhancing Adia's clinic offerings [5][6] Strategic Vision - The CEO of Adia Nutrition expressed enthusiasm about entering the glutathione market, emphasizing the importance of delivering solutions requested by patients and doctors [7] - The company is open to strategic partnerships to expand access to its advanced stem cell solutions [7]